Finance Watch: CellCentric Raises $220m To Advance Myeloma Drug
Private Company Edition: CellCentric will use its $220m in series D venture capital to fund Phase II and III trials of inobrodib. Also, Banyan BioInnovations launched with $100m to build new companies around clinical-stage assets and Windward Bio raised a $165m crossover round.
Scrip - May 6, 2026

As Rezdiffra Launch Progresses, Madrigal Builds Pipeline To Maintain Top MASH Spot
With a strong launch ongoing for Rezdiffra in MASH, Madrigal says Novo Nordisk’s Wegovy is not greatly affecting market share. Dealmaking continues to bolster combo strategy.
Scrip - May 6, 2026

Q1 Earnings Briefs: SMID Caps Build New Blockbuster Brands
As more small/mid-cap biopharmas commercialize their own products, the first quarter sales and earnings calls provide updates on new products that are big growth drivers.
Scrip - May 6, 2026

Avalo’s Abdakibart Successful In HS, But Can It Challenge IL-17 Class?
The Phase II LOTUS study met the primary endpoint and Avalo plans to move the drug into Phase III, but an analyst questioned whether it’s a threat to IL-17 antagonists in hidradenitis suppurativa.
Scrip - May 6, 2026

How Sun Pharma’s Organon Deal Unlocks China’s ‘Hidden Optionality’ And New Markets
The $11.75bn Organon acquisition gives Sun Pharma a platform it has lacked: scale in China, a global footprint for in-licensing and new market footholds across 10 countries. In an interview with Scrip, MD Kirti Ganorkar sets out how Sun plans to move forward.
Scrip - May 6, 2026

Bayer Beefs Up In Ophthalmology With Perfuse Buyout
Bayer is expanding its ophthalmology pipeline beyond Eylea with a deal for Perfuse Therapeutics that could be worth $2.45bn.
Scrip - May 6, 2026

Roche Still Supports Switzerland But Signs Of Strain Showing
CEO Thomas Schinecker talks taxes, pricing and pharma’s contribution to society at Swiss Biotech Day.
Scrip - May 6, 2026

Novo Is Winning In Early Obesity Pill Market But Prices Will Never Be The Same
The Danish company has achieved the best ever obesity launch thanks to consumer enthusiasm for a cut price oral Wegovy
Scrip - May 6, 2026

BioNTech To Cut 1,860 Jobs As Part Of Post-COVID Restructuring
BioNTech is restructuring parts of its pandemic-era manufacturing network and redirecting capital toward late-stage oncology programs as the company prepares for future cancer drug launches amid declining COVID-19 vaccine revenues.
Scrip - May 6, 2026

GSK Bolsters Downstream Obesity Strategy By Gaining SiranBio’s siRNA Drug
GSK is likely to ride the fresh deal to up its game in metabolic dysfunction-associated steatohepatitis (MASH), while still staying out of the increasingly crowded weight-loss space.
Scrip - May 6, 2026

Philips Says Helium-Free Portfolio Insures Providers Against Geoshocks
Philips is targeting a 2027 introduction of helium-free 3T MR systems, building on the momentum of BlueSeal, CEO Roy Jakobs said, as the company announced mid-single-digit comparable sales growth in the first quarter of 2026.
Medtech Insight - May 6, 2026

Recent FDA Device Classifications Include Fujirebio Test For Alzheimer’s Disease
The FDA has announced new regulatory classifications for 13 devices that reached market via the de novo pathway, ranging from diagnostics to digital health tools and surgical instruments.
Medtech Insight - May 6, 2026

B. Braun’s New North America CEO Focuses On Critical Products, Innovation, Customers
Michael Parden succeeds longtime Rob Albert as CEO B. Braun North America this month. Parden, who brings deep cross-functional B. Braun experience, talked to Medtech Insight about his plans including ensuring patient safety, continuing innovation and building stronger customer relationships.
Medtech Insight - May 6, 2026

Makary Introduces One-Day Inspections, Touts Agency’s Embrace Of Bold Ideas
During a fireside chat hosted by the Food and Drug Law Institute on Wednesday, FDA Commissioner Marty Makary noted several agency initiatives, including one-day inspections, hiring more staff, and speeding up approvals.
Medtech Insight - May 6, 2026

Could Do Better: MedTech Europe Supports MDR/IVDR Revision Plan But Wants More
MedTech Europe voiced support for the direction of the European Commission’s MDR/IVDR proposed reform, but called for further changes to ensure workable outcomes for industry.
Medtech Insight - May 6, 2026

Proposed Rule Would Replace ‘Gender’ With ‘Sex’ In US FDA Regulations
The move appears to be another step in the Trump Administration’s diversity, equity and inclusion purge that already has impacted FDA guidances and webpages.
HBW Insight - May 7, 2026

‘Challenging Market Environment’ Slows Perrigo As It Becomes ‘More Focused, Disciplined, Consistent’
CEO Patrick Locwood-Taylor says as Perrigo is “making steady progress in building a more focused, disciplined, and consistent” firm, “we are starting to look at pricing, depending on what happens with other commodity prices.”
HBW Insight - May 7, 2026

Coty: Middle East Conflict Drags Top Line
New York-based Coty reported that the Middle East conflict is expected to shave 2% to 3% off fiscal fourth quarter sales.
HBW Insight - May 7, 2026

Semaglutide Scaling Continues In Canada With Apotex Approval
Already the first G7 nation to move past the brand name for Ozempic, Canada has announced another generic approval, this time for Apotex.
Generics Bulletin - May 6, 2026

Xbrane Looks At Its Opdivo Biosimilar Partner Intas For Cash
A revised Intas deal on nivolumab buys Xbrane some financial breathing room, but the Swedish firm still needs to cut costs on its only revenue-generating product while racing to stay relevant in a crowded eye care market.
Generics Bulletin - May 6, 2026

Two Speeds: The Solid Tumor Markets Racing Ahead And The Ones Left Behind
In this article, the second of the oncology therapeutic review series, In Vivo examines the major solid tumor cancer types driving the oncology market.
In Vivo - May 6, 2026

Biomed 2026: From Device To Healthtech Via Software, Data And AI
Peregrine Ventures’ managing general partner Eyal Lifschitz gave a broad-brush picture of the themes investors, founders and innovators can expect to discuss on a panel session he will co-host at Biomed Israel 2026.
In Vivo - May 6, 2026